How Nucala Reduces Nasal Polyp Swelling: The Anti-IL-5 Tissue Science

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often frustrating condition marked by inflamed tissue growths (polyps) in the nasal passages and sinuses. These polyps can lead to congestion, loss of smell, facial pressure, nasal discharge and recurrent infections. Standard treatments include corticosteroid sprays, short courses of oral steroids and, in some cases, surgery. However, for many patients, polyps recur despite these approaches.

Enter Nucala (mepolizumab), a biologic therapy that targets the underlying immune process driving polyp formation and growth. By blocking interleukin-5 (IL-5), a key protein in the activation and survival of eosinophils (white blood cells that fuel inflammation), Nucala reduces tissue swelling and polyp size. Below, we explore how the "nucala injection for chronic rhinosinusitis with nasal polyps" works, who may benefit, what to expect and when to seek medical advice.

---

The Role of IL-5 and Eosinophils in Nasal Polyps

• IL-5 is a cytokine, a messenger protein that tells eosinophils to mature, survive and gather in inflamed tissues.
• In CRSwNP, IL-5 levels are elevated in nasal tissues and secretions.
• Eosinophils release toxic proteins and inflammatory mediators, causing tissue damage, swelling and polyp formation.
• Repeated cycles of eosinophil-driven inflammation make polyps recur even after steroid treatment or surgery.

By neutralizing IL-5, Nucala interrupts this cycle at the source, leading to fewer eosinophils in nasal tissues and gradual regression of polyps.

---

How Nucala Works: Anti-IL-5 Mechanism

1. Binding IL-5
   Nucala is a monoclonal antibody that specifically binds to free IL-5 in blood and tissue fluid.
2. Preventing Eosinophil Activation
   Without free IL-5, eosinophils cannot mature properly or avoid programmed cell death.
3. Lowering Eosinophil Counts
   Blood tests show a drop in eosinophil levels, mirroring reduced infiltration into the nasal mucosa.
4. Reducing Tissue Swelling
   As fewer eosinophils migrate to sinus tissues, inflammation subsides and polyps shrink.

This targeted approach is different from broad-spectrum steroids, offering the potential for long-term control with fewer systemic side effects.

---

Clinical Evidence of Efficacy

Multiple clinical trials have evaluated "nucala injection for chronic rhinosinusitis with nasal polyps," demonstrating:

• Significant reduction in nasal polyp size (endoscopic scoring).
• Improved nasal obstruction scores and sense of smell.
• Fewer rescue courses of oral steroids.
• Lower rates of sinus surgery over one year.
• Enhanced quality of life measures (e.g., decreased nasal blockage, less facial pain).

Patients with higher baseline blood eosinophil counts tend to show the greatest benefit.

---

Who Is a Candidate?

Nucala is approved for adults with CRSwNP who:

• Have had an inadequate response to nasal corticosteroids.
• Experience recurrent polyps requiring oral steroids or surgery.
• Show elevated eosinophil levels (typically ≥150 cells/µL at screening or ≥300 cells/µL in the past year).

Your doctor may consider factors such as:

• History of asthma or aspirin-exacerbated respiratory disease (often eosinophil-driven).
• Previous surgical history and rate of polyp recurrence.
• Tolerance to injectable therapies and ability to attend regular appointments.

---

Administration and Dosage

• Form: Pre-filled syringe for subcutaneous injection.
• Dosage: 100 mg every four weeks.
• Location: Upper arm, thigh or abdomen (rotating sites).
• Setting: Healthcare provider's office or, in some regions, self-administered after training.
• Monitoring: Periodic blood counts to track eosinophil levels and assess response.

Most patients notice gradual improvement over 3–6 months, with continued gains up to one year.

---

Safety and Side Effects

Common side effects are generally mild to moderate:

• Injection site reactions (redness, swelling, itching)
• Headache
• Back pain
• Fatigue

Less common but important considerations:

• Hypersensitivity reactions (rare; seek immediate care if you develop rash, swelling or breathing difficulty).
• Herpes zoster (shingles) – discuss vaccination status with your doctor.
• Potential risk of parasitic infections (if you live in or travel to areas where worms are common).

Overall, the targeted nature of Nucala means fewer systemic steroid-related risks like weight gain, bone thinning or elevated blood sugar.

---

Benefits Beyond Polyp Reduction

By dampening eosinophil-driven inflammation in the sinuses, patients often experience:

• Improved sleep quality (less mouth breathing and congestion).
• Reduced need for oral corticosteroid courses.
• Fewer unplanned doctor visits or surgeries.
• Better control of coexisting eosinophilic asthma (if present).

These benefits translate into enhanced daily functioning, work productivity and overall well-being.

---

When to Reassess Treatment

Your healthcare team will look at:

• Degree of polyp shrinkage on endoscopy.
• Symptom scores (nasal obstruction, sense of smell, facial pressure).
• Impact on daily activities and quality of life.
• Blood eosinophil trends.

If adequate control isn't achieved after 6–12 months, your doctor may:

• Continue Nucala if there's partial benefit.
• Consider alternative biologics targeting other pathways (e.g., IL-4/IL-13).
• Discuss additional surgical or medical options.

---

Self-Assessment and Next Steps

If you're struggling with persistent nasal congestion, reduced smell, facial pressure or recurrent sinus infections despite standard treatments, you may have uncontrolled CRSwNP fueled by eosinophils. Understanding your symptoms is the first step toward finding effective relief—take Ubie's free AI symptom checker to get personalized insights about your sinus and nasal concerns before your next doctor's appointment.

---

Important Reminder

This information is intended to educate about how Nucala works and who might benefit from a "nucala injection for chronic rhinosinusitis with nasal polyps." It is not a substitute for professional medical advice. Always speak to a doctor about any life-threatening or serious symptoms, unexpected side effects or before starting or stopping any medication.